Search Results

There are 51836 results for: content related to: Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database

  1. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients

    Pediatric Blood & Cancer

    Volume 62, Issue 4, April 2015, Pages: 704–709, Alix E. Seif, Dana M. Walker, Yimei Li, Yuan-Shung V. Huang, Marko Kavcic, Kari Torp, Rochelle Bagatell, Brian T. Fisher and Richard Aplenc

    Version of Record online : 26 MAR 2014, DOI: 10.1002/pbc.25043

  2. You have free access to this content
    PKA-mediated phosphorylation of Dexras1 suppresses iron trafficking by inhibiting S-nitrosylation

    FEBS Letters

    Volume 589, Issue 20PartB, October 07, 2015, Pages: 3212–3219, Yong Chen, Lauren Mathias, Juliana M. Falero-Perez and Sangwon F. Kim

    Version of Record online : 7 SEP 2015, DOI: 10.1016/j.febslet.2015.08.041

  3. You have free access to this content
    The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells

    British Journal of Pharmacology

    Volume 172, Issue 9, May 2015, Pages: 2246–2257, Shiwei Deng, Tiandong Yan, Teodora Nikolova, Dominik Fuhrmann, Andrea Nemecek, Ute Gödtel-Armbrust, Bernd Kaina and Leszek Wojnowski

    Version of Record online : 27 FEB 2015, DOI: 10.1111/bph.13046

  4. Cardioprotective interventions for cancer patients receiving anthracyclines

    Intervention Review

    The Cochrane Library

    Elvira C van Dalen, Huib N Caron, Heather O Dickinson and Leontien CM Kremer

    Published Online : 15 JUN 2011, DOI: 10.1002/14651858.CD003917.pub4

  5. You have free access to this content
    Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity

    British Journal of Pharmacology

    Volume 163, Issue 2, May 2011, Pages: 299–312, RD Spagnuolo, S Recalcati, L Tacchini and G Cairo

    Version of Record online : 18 APR 2011, DOI: 10.1111/j.1476-5381.2011.01208.x

  6. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients

    Pediatric Blood & Cancer

    Volume 44, Issue 7, 15 June 2005, Pages: 584–588, Barry Anderson

    Version of Record online : 7 FEB 2005, DOI: 10.1002/pbc.20358

  7. Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline-Induced Cardiotoxicity

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 45–52, P Vejpongsa and ETH Yeh

    Version of Record online : 19 DEC 2013, DOI: 10.1038/clpt.2013.201

  8. An In Vitro Comparison of the Effects of the Iron-Chelating Agents, CP94 and Dexrazoxane, on Protoporphyrin IX Accumulation for Photodynamic Therapy and/or Fluorescence Guided Resection

    Photochemistry and Photobiology

    Volume 87, Issue 6, November/December 2011, Pages: 1419–1426, Emma Blake, James Allen and Alison Curnow

    Version of Record online : 16 SEP 2011, DOI: 10.1111/j.1751-1097.2011.00985.x

  9. You have free access to this content
    Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for IKs

    British Journal of Pharmacology

    Volume 159, Issue 1, January 2010, Pages: 93–101, J Ducroq, H Moha ou Maati, S Guilbot, S Dilly, E Laemmel, C Pons-Himbert, JF Faivre, P Bois, O Stücker and M Le Grand

    Version of Record online : 24 AUG 2009, DOI: 10.1111/j.1476-5381.2009.00371.x

  10. Rhes and AGS1/Dexras1 affect signaling by dopamine D1 receptors through adenylyl cyclase

    Journal of Neuroscience Research

    Volume 89, Issue 6, June 2011, Pages: 874–882, Laura M. Harrison and YouE He

    Version of Record online : 3 MAR 2011, DOI: 10.1002/jnr.22604

  11. Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function

    The Journal of Clinical Pharmacology

    Volume 51, Issue 5, May 2011, Pages: 731–738, Dr Michael E. Brier, Ms Shari K. Gaylor, Dr J. Patrick McGovren, Dr Paul Glue, Dr Annie Fang and Dr George R. Aronoff

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010369675

  12. Circadian abnormalities in mouse models of smith–magenis syndrome: Evidence for involvement of RAI1

    American Journal of Medical Genetics Part A

    Volume 161, Issue 7, July 2013, Pages: 1561–1568, Melanie Lacaria, Wenli Gu and James R Lupski

    Version of Record online : 23 MAY 2013, DOI: 10.1002/ajmg.a.35941

  13. Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient

    Veterinary and Comparative Oncology

    Volume 8, Issue 4, December 2010, Pages: 273–282, W. M. FitzPatrick, N. G. Dervisis and B. E. Kitchell

    Version of Record online : 10 NOV 2010, DOI: 10.1111/j.1476-5829.2010.00225.x

  14. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma

    Journal of Clinical Pharmacy and Therapeutics

    Volume 39, Issue 2, April 2014, Pages: 168–174, S. Limat, E. Daguindau, J.-Y. Cahn, V. Nerich, A. Brion, S. Perrin, M.-C. Woronoff-Lemsi and E. Deconinck

    Version of Record online : 3 JAN 2014, DOI: 10.1111/jcpt.12124

  15. You have free access to this content
    Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats

    British Journal of Pharmacology

    Volume 151, Issue 6, July 2007, Pages: 771–778, D Lebrecht, A Geist, U-P Ketelsen, J Haberstroh, B Setzer and U A Walker

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0707294

  16. You have free access to this content
    Association of HLA–C3 and smoking with vasculitis in patients with rheumatoid arthritis

    Arthritis & Rheumatism

    Volume 54, Issue 9, September 2006, Pages: 2776–2783, Carl Turesson, Daniel J. Schaid, Cornelia M. Weyand, Lennart T. Jacobsson, Jörg J. Goronzy, Ingemar F. Petersson, Sonja A. Dechant, Britt-Marie Nyähll-Wåhlin, Lennart Truedsson, Gunnar Sturfelt and Eric L. Matteson

    Version of Record online : 31 AUG 2006, DOI: 10.1002/art.22057

  17. You have free access to this content
    Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients

    American Journal of Hematology

    Volume 87, Issue 8, August 2012, Pages: 830–832, Anat Rabinovich, Dana Weiss, Maya Weissman, Victor Novack and Itai Levi

    Version of Record online : 31 MAY 2012, DOI: 10.1002/ajh.23250

  18. You have free access to this content
    Prevention of cardiotoxicity among survivors of childhood cancer

    British Journal of Clinical Pharmacology

    Kelley K. Hutchins, Hani Siddeek, Vivian I. Franco and Steven E. Lipshultz

    Version of Record online : 12 OCT 2016, DOI: 10.1111/bcp.13120

  19. You have free access to this content
    Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat

    British Journal of Pharmacology

    Volume 131, Issue 1, September 2000, Pages: 1–4, Briant E Burke, Hervé Gambliel, Richard D Olson, Frederic K Bauer and Barry J Cusack

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0703538

  20. You have free access to this content
    Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group

    Pediatric Blood & Cancer

    Volume 63, Issue 1, January 2016, Pages: 54–61, Cindy L. Schwartz, Leonard H. Wexler, Mark D. Krailo, Lisa A. Teot, Meenakshi Devidas, Laurel J. Steinherz, Allen M. Goorin, Mark C. Gebhardt, John H. Healey, Judith K. Sato, Paul A. Meyers, Holcombe E. Grier, Mark L. Bernstein and Steven E. Lipshultz

    Version of Record online : 23 SEP 2015, DOI: 10.1002/pbc.25753